Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machin...
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
- Associated Therapies
- -
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 198
- Registration Number
- NCT06524583
- Locations
- 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷Institut Paoli Calmettes, Marseille, France
🇫🇷Centre Francois Baclesse, Caen, France
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Intensity Therapeutics, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT06263231
- Locations
- 🇺🇸
The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
tTF-NGR Randomized Study - STS
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 126
- Registration Number
- NCT05597917
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Germany
🇩🇪HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 190
- Registration Number
- NCT05432791
- Locations
- 🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 85
- Registration Number
- NCT05131386
- Locations
- 🇪🇸
Hospital General Universitario Gregorio Marañón, Madrid, Comunidad De Madrid, Spain
🇪🇸Hospital Universitario de Canarias, Tenerife, Islas Canarias, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña, Spain
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Rain Oncology Inc
- Target Recruit Count
- 175
- Registration Number
- NCT04979442
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Miami Hospital & Clinics - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 10
- Registration Number
- NCT04794127
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milano, MI, Italy
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Sarcoma Oncology Research Center, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT04535271
- Locations
- 🇺🇸
Sant P Chawla, Santa Monica, California, United States
Pharmacometabolomic of Trabectedin in Soft Tissue Patients
- Conditions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 44
- Registration Number
- NCT04394728
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 100
- Registration Number
- NCT04383119
- Locations
- 🇮🇹
Nuovo Ospedale di Prato, Prato, Firenze, Italy
🇮🇹IRCCS Fondazione Piemonte per l'Oncologia, Candiolo, Torino, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola, FC, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.